.Nature Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in boosted progression-free and general survival, resulting in FDA approval and a brand-new therapy choice for patients.